145 related articles for article (PubMed ID: 19932214)
1. Alpha-fetoprotein in early hepatocellular carcinoma.
Marrero JA; Feng Z
Gastroenterology; 2010 Jan; 138(1):400-1. PubMed ID: 19932214
[No Abstract] [Full Text] [Related]
2. Alpha-fetoprotein in hepatocellular carcinoma surveillance: wake not the dead.
Giannini EG; Farinati F; Trevisani F
Hepatology; 2011 Jul; 54(1):376-7. PubMed ID: 21710475
[No Abstract] [Full Text] [Related]
3. Spontaneous drastic reduction of alpha-fetoprotein in hepatocellular carcinoma.
Phadke AY; Desai HG
Indian J Gastroenterol; 1996 Jul; 15(3):111. PubMed ID: 8840646
[TBL] [Abstract][Full Text] [Related]
4. Serum tests for diagnosis and follow-up of hepatocellular carcinoma after treatment.
Trojan J; Raedle J; Zeuzem S
Digestion; 1998 Jul; 59 Suppl 2():72-4. PubMed ID: 9718428
[No Abstract] [Full Text] [Related]
5. Alpha-fetoprotein: a controversial prognostic biomarker for small hepatocellular carcinoma.
Asrih M; Lenglet S; Mach F; Montecucco F
World J Gastroenterol; 2013 Jan; 19(3):328-30. PubMed ID: 23372353
[TBL] [Abstract][Full Text] [Related]
6. History and recent progress in evaluation of the fucosylated alpha-fetoprotein fraction.
Aoyagi Y; Tamura Y; Suda T
J Gastroenterol Hepatol; 2011 Apr; 26(4):615-6. PubMed ID: 21418297
[No Abstract] [Full Text] [Related]
7. Extremely High Preoperative Alpha-Fetoprotein Level Is Associated with Vascular Invasion, Non-R0 Resection, and Poor Prognosis in Hepatocellular Carcinoma Patients.
Zhang Y; Huang P; Zheng Y; Wang Y; Yuan Y; He W; Liu W; Yang Z; Wang C; Yuan Y; Li B
Am Surg; 2019 Jun; 85(6):e309-e312. PubMed ID: 31267923
[No Abstract] [Full Text] [Related]
8. Alpha-fetoprotein response in advanced hepatocellular carcinoma receiving cytostatic agent.
Chen LT; Shiah HS; Chao Y; Chang JY; Cheng LT; Whang-Peng J
J Clin Oncol; 2009 Dec; 27(36):e271; author reply e272. PubMed ID: 19917866
[No Abstract] [Full Text] [Related]
9. Serum golgi phosphoprotein 2 level: a better marker than alpha-fetoprotein for diagnosing early hepatocellular carcinoma.
Li X; Wu K; Fan D
Hepatology; 2009 Nov; 50(5):1682. PubMed ID: 19739256
[No Abstract] [Full Text] [Related]
10. VWF/ADAMTS13 ratio as a potential biomarker for early detection of hepatocellular carcinoma.
Takaya H; Namisaki T; Kitade M; Kaji K; Nakanishi K; Tsuji Y; Shimozato N; Moriya K; Seki K; Sawada Y; Saikawa S; Sato S; Kawaratani H; Akahane T; Noguchi R; Matsumoto M; Yoshiji H
BMC Gastroenterol; 2019 Oct; 19(1):167. PubMed ID: 31638892
[TBL] [Abstract][Full Text] [Related]
11. A comparison between alpha-fetoprotein and p53 antibodies in the diagnosis of hepatocellular carcinoma.
Edis C; Kähler C; Klotz W; Herold M; Feichtinger H; Königsreiner A; Margreiter R; Jaschke W; Vogel W
Transplant Proc; 1998 May; 30(3):780-1. PubMed ID: 9595095
[No Abstract] [Full Text] [Related]
12. Plasma osteopontin level as a diagnostic marker of hepatocellular carcinoma in patients with radiological evidence of focal hepatic lesions.
Khalil A; Elgedawy J; Faramawi MF; Elfert A; Salama I; Abbass A; Elsaid H; Elsebaai H
Tumori; 2013; 99(1):100-7. PubMed ID: 23549008
[TBL] [Abstract][Full Text] [Related]
13. Spontaneous regression of hepatocellular carcinoma.
Kondo S; Okusaka T; Ueno H; Ikeda M; Morizane C
Int J Clin Oncol; 2006 Oct; 11(5):407-11. PubMed ID: 17058140
[TBL] [Abstract][Full Text] [Related]
14. Elevated alpha-fetoprotein: differential diagnosis - hepatocellular carcinoma and other disorders.
Wong RJ; Ahmed A; Gish RG
Clin Liver Dis; 2015 May; 19(2):309-23. PubMed ID: 25921665
[TBL] [Abstract][Full Text] [Related]
15. Assessment of the Clinical Utility of Glypican 3 as a Serum Marker for the Diagnosis of Hepatocellular Carcinoma.
Jia X; Gao Y; Zhai D; Liu J; Cai J; Wang Y; Jing L; Du Z
Technol Cancer Res Treat; 2016 Dec; 15(6):780-786. PubMed ID: 26370140
[TBL] [Abstract][Full Text] [Related]
16. Hepatocellular carcinoma: patients with increasing alpha-fetoprotein but no mass on ultrasound.
Llovet JM
Clin Gastroenterol Hepatol; 2006 Jan; 4(1):29-35. PubMed ID: 16431301
[No Abstract] [Full Text] [Related]
17. Contribution of biomarkers and imaging in the management of hepatocellular carcinoma.
Fartoux L; Decaens T
Clin Res Hepatol Gastroenterol; 2011 Jun; 35 Suppl 1():S21-30. PubMed ID: 21742297
[TBL] [Abstract][Full Text] [Related]
18. Hepatocellular carcinoma, a unique tumor with a lack of biomarkers.
Debes JD; Carrera E; Mattos AZ; Prieto JE; Boonstra A;
Ann Hepatol; 2019; 18(6):786-787. PubMed ID: 31494068
[TBL] [Abstract][Full Text] [Related]
19. Screening and detection of hepatocellular carcinoma.
Simpson HN; McGuire BM
Clin Liver Dis; 2015 May; 19(2):295-307. PubMed ID: 25921664
[TBL] [Abstract][Full Text] [Related]
20. Serum alpha 1-antitrypsin in patients with hepatocellular carcinoma.
Lee HB; Yoo OJ; Ham JS; Lee MH
Clin Chim Acta; 1992 Mar; 206(3):225-30. PubMed ID: 1376649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
